INSULET CORP (PODD) Risk Factors
Health CareLatest 10-K filed Feb 18, 2026Source: SEC EDGAR
WealthWire extracted and classified 42 risk factors from INSULET CORP’s latest SEC filing, mapping each to a standardized risk taxonomy so they can be compared across every company and sector. The breakdown below shows how those disclosures distribute across risk categories.
Legal & regulatory
10 factorsMarket & business
8 factorsTechnology
7 factorsOperations & people
7 factorsFinancial
5 factorsHealthcare & life sciences
3 factorsOther
1 factorsESG & reputation
1 factorsRecent key developments
Concrete developments — dated events, named agreements and instruments, legal proceedings — that INSULET CORP surfaced in its latest filing.
- Substantially all commercialized Drug Delivery revenue comes from customized pods for Amgen's Neulasta Onpro kit under an agreement expiring December 2028.December 2028
- Medtronic Diabetes is a division of Medtronic plc spinning out into a new independent company.
- International sales made up 28% of our revenues in 2025.2025
- BIS initiated a Section 232 investigation into imports of personal protective equipment, medical consumables, and medical equipment, including medical devices such as insulin pumps.
- We have a partnership with Glooko for cloud-based diabetes data management; the agreement expires in December 2026.December 2026
- EU AI Act is taking effect in stages through August 2026.August 2026
- In 2025, Insulet experienced changes in key leadership roles, including the Chief Executive Officer and Chief Financial Officer, among others.2025
- In 2023, speculation about GLP-1 drugs for obesity negatively impacted medical device company stock prices, including ours.2023
Go deeper on PODD
This page shows the category breakdown of the latest filing. The WealthWire API and dashboard add the full risk-factor text, multi-year trends, sector comparisons, and CSV export — for PODD and every other S&P 500 company.